What is 180 Life Sciences Profitability Rank?
180 Life Sciences has the Profitability Rank of 1. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1.
Operating Margin %
2.
Piotroski F-Score
3. Trend of the
Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
180 Life Sciences's Operating Margin % for the quarter that ended in Dec. 2023 was %. As of today, 180 Life Sciences's Piotroski F-Score is 1.
Competitive Comparison of 180 Life Sciences's Profitability Rank
For the Biotechnology subindustry, 180 Life Sciences's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
180 Life Sciences's Profitability Rank Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 180 Life Sciences's Profitability Rank distribution charts can be found below:
* The bar in red indicates where 180 Life Sciences's Profitability Rank falls into.
180 Life Sciences Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
180 Life Sciences has the Profitability Rank of 1. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
180 Life Sciences's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
Warning Sign:
Piotroski F-Score of 1 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
180 Life Sciences has an F-score of 1. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
180 Life Sciences (180 Life Sciences) Business Description
Traded in Other Exchanges
N/A
Address
3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, CA, USA, 94306
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics.
Executives
| James N. Woody |
director, officer: Chief Executive Officer |
C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063 |
| Marc Feldmann |
director |
5 DURHAM TERRACE, LONDON X0 W25PB |
| Lawrence Steinman |
director |
10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121 |
| Mcgovern Jr. Donald A. |
director |
C/O CARS.COM, 300 S. RIVERSIDE PLAZA, SUITE 1000, CHICAGO IL 60606 |
| Quan Anh Vu |
officer: COO / Chief Business Officer |
22616 ERWIN STREET, WOODLAND HILLS CA 91367 |
| Ozan Pamir |
officer: Interim CFO |
2443 FILLMORE ST #380-17649, SAN FRANCISCO CA 94115 |
| Pamela G Marrone |
director |
C/O MARRONE BIO INNOVATIONS, INC., 2121 SECOND STREET, A-107, DAVIS CA 95618 |
| Teresa Deluca |
director |
40 BURTON HILLS BOULEVARD, SUITE 500, NASHVILLE TN 37215 |
| Russell T Ray |
director |
2525 DUPONT DR, IRVINE CA 92612 |
| Knuettel Ii Francis |
director |
205 NEWBURY ST, SUITE 204, FRAMINGHAM MA 01701 |
| Marlene Krauss |
director, 10 percent owner, officer: Chief Executive Officer |
C/O KBL HEALTHCARE INC, 645 MADISON AVE, NEW YORK NY 10022 |
| Lawrence Marshall Gold |
director |
830 MENLO AVENUE, SUITE 100, MENLO PARK CA 94025 |
| Jonathan B. Rothbard |
officer: Chief Scientific Officer |
501 BEALE STREET, UNIT 8D, SAN FRANCISCO CA 94105 |
| Shoshana Shendelman |
director |
C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173 |
| Richard W Barker |
director |
290 COMMONWEALTH AVENUE #17, BOSTON MA 02115 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ATNF has been successfully added to your